Kavigale

Sipavibart, the active ingredient in Kavigale, is a pharmaceutical compound presented as an injectable solution for intramuscular and intravenous use. It is being investigated for potential therapeutic applications in various disease areas.

GNH USA supplies Kavigale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Sipavibart is currently under clinical investigation and does not have approved therapeutic indications.

- No approved indication: currently not authorized for clinical use. - Research use – infectious disease: being studied for potential antiviral activity. - Research use – inflammatory disorders: evaluated for modulation of inflammatory pathways. - Research use – oncology: explored as a candidate in early‑phase cancer trials.

Adverse reactions reported in early clinical studies are limited and primarily related to the route of administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema and edema. - Fever: transient low‑grade temperature rise. - Headache: mild to moderate intensity. - Nausea: occasional mild gastrointestinal upset. - Fatigue: transient feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure post‑administration. - Thrombocytopenia: marked reduction in platelet count. - Hepatic enzyme elevation: significant increase in liver function tests. - Immune‑mediated reactions: such as serum sickness. - Multi‑organ dysfunction: rare cases of systemic involvement.

When handling Sipavibart, clinicians should observe standard safety measures and consider patient‑specific factors.

- Patient assessment: evaluate allergy history before administration. - Monitoring: observe vital signs during and after injection. - Contraindications: avoid in patients with known hypersensitivity to Sipavibart. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; consider potential risk to the infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Potential drug interactions for Sipavibart are not fully characterized; caution is advised with agents that affect immune function or hemostasis.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy. - Immunosuppressants: possible additive immunomodulation. - Anticoagulants: increased risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP450 substrates: potential metabolic interaction; monitor levels. - Antihistamines: may mask early allergic signs. - NSAIDs: could enhance renal adverse effects.